Citius Oncology (CTOR) | Stock Overview & Key Data
Citius Oncology Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $49.00 on August 5, 2024
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Financial Highlights
Profitability
Returns and Earnings
Growth
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Citius Oncology CTOR | 304.81M Small-cap | -38.56% | 153.91% | 424.19% | 182.61% | 173.11% | -61.96% | -57.03% | -57.03% |
| Zoetis ZTS | 70.56B Large-cap | 2.18% | -6.53% | -0.27% | -2.53% | -2.11% | -9.02% | -10.56% | 16.11% |
| Haleon Plc - ADR HLN | 45.53B Large-cap | -1.37% | -7.16% | 4.98% | 11.10% | 7.10% | 12.92% | 35.63% | 35.63% |
| Indivior PLC INDV | 1.92B Small-cap | -0.26% | 12.27% | 71.92% | 29.70% | 22.96% | 39.67% | 322.91% | 1,369.90% |
| BioCryst BCRX | 1.84B Small-cap | -0.67% | -19.35% | 38.53% | 15.78% | 13.41% | 26.71% | -22.23% | 79.76% |
| Supernus SUPN | 1.83B Small-cap | 3.63% | -0.36% | 6.66% | -11.60% | -9.03% | 14.15% | 10.07% | 35.00% |
Ownership & Short Interest
Citius Oncology Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Citius Oncology would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
What is CTOR's 52-week high and low?
In the last 52 weeks, Citius Oncology reached a high of $49.00 (on August 6, 2024) and a low of $0.55 (on March 17, 2025).
What is the market cap and P/E ratio for CTOR?
Curious about Citius Oncology's size and valuation? Its market capitalization stands at 304.81M. When it comes to valuation, the P/E ratio (trailing twelve months) is -14.00, and the forward P/E (looking ahead) is N/A.
Does CTOR pay dividends? If so, what's the yield?
As for dividends, Citius Oncology isn't currently offering a significant yield, or that specific data isn't available right now.
Who are Citius Oncology's main competitors or similar companies to consider before investing?
When looking at Citius Oncology, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
| Company | Mkt Cap | Sector | Industry | 1Y Return | 3Y Return |
|---|---|---|---|---|---|
| Zoetis ZTS | 70.56B | Healthcare | Drug Manufacturers - Specialty & Generic | -9.02% | -10.56% |
| Haleon Plc - ADR HLN | 45.53B | Healthcare | Drug Manufacturers - Specialty & Generic | 12.92% | 35.63% |
| Indivior PLC INDV | 1.92B | Healthcare | Drug Manufacturers - Specialty & Generic | 39.67% | 322.91% |
| BioCryst BCRX | 1.84B | Healthcare | Drug Manufacturers - Specialty & Generic | 26.71% | -22.23% |
| Supernus SUPN | 1.83B | Healthcare | Drug Manufacturers - Specialty & Generic | 14.15% | 10.07% |
For a more comprehensive list, please see the Peer Performance Comparison table on this page.
What are the key financial health indicators for Citius Oncology Inc.? (e.g., ROE, Debt/Equity)
To get a sense of Citius Oncology's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -93.64%, the Debt to Equity ratio from the most recent quarter is 10.66, and its Gross Profit Margin stands at N/A.
What is the recent revenue and earnings growth for CTOR?
Looking at Citius Oncology's growth, its revenue over the trailing twelve months (TTM) was $0. Compared to the same quarter last year (YoY), quarterly revenue grew by N/A, and quarterly earnings saw a YoY growth of N/A.
How much of CTOR stock is held by insiders and institutions?
Wondering who owns Citius Oncology stock? Company insiders (like executives and directors) hold about 95.08% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 0.76%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.